**Table i.** Minimum reporting requirements for clinical studies evaluating mesenchymal stem cells (MIBO checklist) This checklist could be used to guide authors, reviewers, and editors to ensure that submitted manuscripts report sufficient experimental detail to enable results to be evaluated and experiments repeated. (Published with permission from **Murray IR, Geeslin AG, Goudie EB, Petrigliano FA, LaPrade RF)**. Minimum Information for Studies Evaluating Biologics in Orthopaedics (MIBO): Platelet-Rich Plasma and Mesenchymal Stem Cells. *J Bone Joint Surg Am*. 2017;99(10): 809-819.

| Section or topic | Item no. | Checklist item |
|---|---|---|
| Study design | 1 | Study conducted in accordance with CONSORT (RCT), STROBE (cohort, case-control, or cross-sectional), or PRISMA (meta-analysis) guidelines |
| | 2 | Relevant institutional and ethical approval |
| Recipients | 3 | Recipient demographics (including age and sex) |
| | 4 | Comorbidities (including underlying diabetes, inflammatory conditions, preexisting joint pathology, and smoking status) |
| | 5 | Current anti-inflammatory medications |
| Injury | 6 | Diagnosis (including relevant grading system and chronicity) |
| | 7 | Previous treatments for current injury |
| Intervention | 8 | Surgical intervention described sufficiently to enable replication |
| | 9 | Operative findings |
| Donors | 10 | Donor age |
| Tissue harvest | 11 | Tissue harvest described sufficiently to enable replication (including anatomical source, equipment, reagents, storage media, and environment) |
| | 12 | Time between tissue harvest and processing |
| Processing | 13 | Description of tissue processing that makes replication of the experiment possible (including digestion solution concentrations and volumes, duration, agitation and temperature of digestion phase, and name of commercial system) |
| | 14 | If performed, purification described sufficiently to enable replication (including combination and concentration of antibodies, equipment, and method of confirming purity) |
| | 15 | Yield with respect to volume of tissue processed |
| Cell culture | 16 | If performed, cell culture described sufficiently to enable replication (including conditions and number of freeze-thaw cycles) |
| | 17 | If performed, predifferentiation described sufficiently to enable replication |
| MSC characteristics | 18 | MSC preparation and source described in title and abstract (e.g. BM-MSC and ADSC) |
| | 19 | Cellular composition and/or heterogeneity |
| | 20 | Immunophenotype and details of in vitro differentiation tested on batch |
| | 21 | Passage and percentage viability |
| Delivery | 22 | MSC delivery described sufficiently to enable replication (including point of delivery, volume of suspension, and media used as vehicle) |
| | 23 | If performed, details of co-delivered growth factors, scaffolds, or carriers |
| Postoperative care | 24 | Rehabilitation protocol sufficiently described to enable replication (including immobilization and physical therapy) |
| Outcome | 25 | Outcome assessments include functional outcomes and recording of complications (including infection and tumour); if performed, radiological outcomes, physical examination findings, return to activities, and satisfaction |

ADSC, adipose-derived stem cell; BM-MSC, bone marrow mesenchymal stem cells; MSC, mesenchymal stem cell; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RCT, randomized controlled trial.

©2020 The British Editorial Society of Bone & Joint Surgery

**Table ii.** Web links relevant for the reporting of illegitimate providers of cell therapies.

| Region | Link |
|---|---|
| USA | Federal Trade Commission (FTC). Consumer complaints can be made about clinics making unsubstantiated marketing claims of the stem cell products they offer: www.ftc.gov/faq/consumer-protection/submit-consumer-complaint-ftc |
| | Food and Drug Administration (FDA). The FDA has a form for patients who experience adverse events related to human medical products, including unauthorized 'treatments from stem cell clinics': www.fda.gov/consumers/consumer-updates/how-report-product-problems-and-complaints-fda |
| | Federation of State Medical Boards (FSMB). To report a doctor through the FSMB: www.fsmb.org/siteassets/advocacy/policies/fsmb-stem-cell-workgroup-report.pdf |
| Europe | European Medicines Agency. www.ema.europa.eu/en/about-us/how-we-work/handling-reports-alleged-improprieties-external-sources |
| United Kingdom | Advertising standards agency (ASA). For reporting unproven medical claims in advertising: www.asa.org.uk/make-a-complaint.html |
| | Human Tissue Authority. www.hta.gov.uk/reporting-incident-or-concern |
| Australia | Australian Department of Health, Therapeutic Goods Administration. Complaints about false advertising and adverse outcomes from the administration and marketing of unproven medical products: www.tga.gov.au/advertising-complaints-and-outcomes |
| Canada | Health Canada. Report if a clinic is advertising or offering unauthorized stem cell therapies in Canada, or the reporting of adverse events: www.healthycanadians.gc.ca/apps/radar/MD-IM-0005.08.html |
| | Competition Bureau. Unsubstantiated advertising claims: www.competitionbureau.gc.ca/eic/site/cb-bc.nsf/frm-eng/GH%C3%89T-7TDNA5 |
| France | Agence Nationale de Securite du Medicament et des produits de Sante (ANSM). French agency handling administration of unapproved cell therapies or reporting adverse events that have resulted from them: www.ansm.sante.fr/Services/Signalement-Alerte |
| New Zealand | Commerce Commission of New Zealand. Complaints regarding the offering of unlawful therapies or making unfounded marketing claims for unproven cell therapies: www.comcom.govt.nz/make-a-complaint |